F16 IL2 fusion protein - Philogen

Drug Profile

F16 IL2 fusion protein - Philogen

Alternative Names: F-16-IL-2; Teleukin

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I Acute myeloid leukaemia
  • Discontinued Breast cancer; Haemangiosarcoma; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2016 Discontinued - Phase-II for Breast cancer (Combination therapy) in Italy (IV)
  • 08 Sep 2016 Discontinued - Phase-II for Haemangiosarcoma (Combination therapy) in Europe (IV)
  • 08 Sep 2016 Discontinued - Phase-II for Malignant melanoma (Combination therapy) in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top